Guerbet Worldwide
Asia Pacific
Belgium
Brazil
France
Germany
Italy
Japan
Korea
Mexico
Turkey
United Kingdom
USA
MEDEX
SIMAFEX
Cours de l'action
95.52 €
English
/
Français
Our Group
Patients
Our products
R&D Innovation
Investors
Careers
Our Group
News
2013
2012
2011
2010
2009
2008
2007
2006
Guerbet in figures
Our History
Group Introduction Video
Our organization
Our mission serving medical imaging
Vision and Values
Our QSE policy
Guerbet Worldwide
Home
>
Our Group
>
News
>
2012
News
2011 revenue
09.02.2012 08:00
Strong and steady growth driven by Dotarem and Lipiodol
Read the Press Release
<- Back to: 2012